VPC
IMVT icon

Vestal Point Capital’s Immunovant IMVT Stock Holding History

Vestal Point Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-350,000
Closed -$5.98M – 77
2025
Q1 		$5.98M Buy
350,000
+305,000
+678% +$6.38M 0.43% 41
2024
Q4 		$1.11M Buy
+45,000
New +$1.28M 0.07% 70

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Vestal Point Capital's IMVT Position: Q2 2025 in Review

Vestal Point Capital sold out of Immunovant (IMVT) in Q2 2025, closing a stake of 350,000 shares — an estimated $5.98M sold.

Vestal Point Capital first reported a position in IMVT in Q4 2024 and held it in 2 quarters. The position peaked at $5.98M in Q1 2025. 168 funds tracked by Wall St. Rank hold IMVT as of Q2 2025.

  • Vestal Point Capital reported no remaining Immunovant position as of Q2 2025 after selling out during the quarter.
  • Vestal Point Capital sold 350,000 Immunovant shares in Q2 2025, an estimated $5.98M.
  • Vestal Point Capital first reported a position in Immunovant in Q4 2024 and held it in 2 quarters.
  • Vestal Point Capital's Immunovant position peaked at $5.98M in Q1 2025.
  • 168 funds tracked by Wall St. Rank held Immunovant as of Q2 2025.

Based on Vestal Point Capital's 13F filing for Q2 2025, filed 14 Aug 2025.